Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Slideshows|July 8, 2026
7 Drugs Approved for Primary Care: Q2 2026
Author(s)Sydney Jennings
Fact checked by: Abigail Brooks, MA
Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.
Advertisement
Advertisement
The FDA approved several new or expanded treatment options during the second quarter of 2026 with direct implications for conditions commonly managed or identified in primary care, including obesity, hypertension, diabetes, acne, urinary tract infection, HIV-1 infection, and COVID-19 exposure. The approvals include first-in-class or first-in-category agents, new combination therapies, and options that may affect prescribing conversations, referral decisions, and patient counseling in routine clinical practice.
Related to this article
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Advertisement
Advertisement